Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly.
Program (Target) | Potential Indication(s) | First-in-Human (Phase 1) | Proof-of-Concept (Phase 2) |
Pivotal | Approved (a) | Major Market Rights | |
---|---|---|---|---|---|---|---|
Margetuximab (HER2) |
HER2+ Breast |
placeholder
|
placeholder
|
placeholder
|
placeholder
|
![]() |
Greater China ![]() |
HER2+ Gastric/GEJ (+retifanlimab/tebotelimab) |
placeholder
|
placeholder
|
|||||
Flotetuzumab (CD123 × CD3) |
Refractory AML |
placeholder
|
placeholder
|
placeholder
|
![]() |
||
Retifanlimab(b) (PD-1) |
NSCLC, Anal |
placeholder
|
placeholder
|
placeholder
|
![]() |
Greater China ![]() |
|
Enoblituzumab (B7–H3) |
SCCHN (+retifanlimab/tebotelimab) |
|
placeholder
Planned 1Q21
|
![]() |
Greater China ![]() |
||
Tebotelimab (PD-1 × LAG-3) |
Solid Tumors & Heme Malignancies |
placeholder
|
placeholder
|
![]() |
Greater China ![]() |
||
MGD019 (PD-1 × CTLA-4) |
MSS-Colorectal, NSCLC |
placeholder
|
![]() |
||||
MGC018 (B7-H3) |
mCRPR, TNBC, NSCLC |
placeholder
|
![]() |
||||
IMGC936 (ADAM9) |
Solid Tumors |
placeholder
|
50/50 Collaboration![]() ![]() |
||||
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
placeholder
|
placeholder
|
placeholder
|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
placeholder
|
placeholder
|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
placeholder
|
placeholder
|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
Planned 1Q21
|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
placeholder
|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
placeholder
|
Phase 1 | Phase 2 | Pivotal | Approved |
---|---|---|---|
placeholder
|